



1635
Hw

TRANSMITTAL LETTER

Docket No.
30566/30029

Application No.
09/920,033-Conf. #5785

Filing Date
August 1, 2001

Examiner
J. Epps-Ford, Ph.D.

Art Unit
1635

Applicant(s): Rosanne M. Crooke et al.

Invention: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION


TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is a request for reconsideration in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims		- =		X	
Independent Claims		- =		X	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					

- ☐ Large Entity ☐ Small Entity
- ☐ No additional fee is required for this amendment.
- ☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 13-2855 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.


Thomas J. Wrona
Attorney Reg. No.: 44,410

Dated: November 5, 2004

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 5, 2004

Signature:  (Thomas J. Wrona)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: October 5, 2004

Signature

(Thomas J. Wrona, Ph.D.)

Docket No.: 30566/30029
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Rosanne M. Crooke, *et al.*

Application No.: 09/920,033

Group Art Unit: 1635

Filed: August 1, 2001

Examiner: J. Epps-Ford, Ph.D.

For: ANTISENSE MODULATION OF
APOLIPOPROTEIN B EXPRESSION

REQUEST FOR RECONSIDERATION UNDER 37 C.F.R. § 1.112

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action of August 5, 2004, Applicant requests reconsideration of claims 1, 2, 4-14, and 20-26 in light of the following remarks.

I. The Outstanding Rejections

Claims 1-2, 4-14, and 20-26 stand rejected under 35 U.S.C. § 112, first paragraph, for assertedly failing to comply with the written description requirement.

Claims 1-2, 4-14, and 20-23 stand rejected under 35 U.S.C. § 103(a) as assertedly being unpatentable over Chan et al. (WO 01/12789 A2) in view of Branch, Monia et al, and Agrawal et al.

II. Patentability Arguments

A. The rejection under 35 U.S.C. § 112, first paragraph

Claims 1-2, 4-14, and 20-26 stand rejected under 35 U.S.C. § 112, first paragraph, as assertedly failing to comply with the written description requirement. Specifically, the rejection asserts that the range of nucleotides 1-114 or nucleotides 151-14121 of SEQ ID NO:3 is not supported by the specification as filed. Although the Examiner concedes that the end points of the recited ranges are supported, e.g., in Table 1, the Examiner asserts that "the